Compass therapeutics announces presentation of updated results from the ongoing phase 2 study of ctx-009 in biliary tract cancer (btc) at the 2023 asco gi cancers symposium january 19-21

Boston, dec. 15, 2022 (globe newswire) -- compass therapeutics, inc. (nasdaq: cmpx), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that updated results from the ongoing phase 2 study of ctx-009 combined with paclitaxel in patients with biliary tract cancer (btc) will be presented at a poster session of the 2023 american society of clinical oncology gastrointestinal cancers symposium (asco gi) taking place in san francisco, ca january 19-21, 2023. additional poster presentations by compass include trials in progress posters for the ongoing phase 2/3 study of ctx-009 combined with paclitaxel in patients with biliary tract cancers (btc) and the ongoing phase 2 study of ctx-009 in patients with metastatic colorectal cancer (crc).
CMPX Ratings Summary
CMPX Quant Ranking